In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 191 to 200 of 435

TitleTypeExpected publication date
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes ID6499Technology appraisal guidance
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]Technology appraisal guidanceTBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidance
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All